Athena Athena

X
[{"orgOrder":0,"company":"Maruho","sponsor":"BiomX","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BiomX Announces Agreement with Maruho Co., Ltd. for Atopic Dermatitis Product Candidate BX005","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"JAPAN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical"},{"orgOrder":0,"company":"Maruho","sponsor":"Journey Medical Corporation","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"QBREXZA\u00ae (Rapifort\u00ae Wipes 2.5%) Receives Manufacturing and Marketing Approval in Japan Triggering $2.5 Million Milestone Payment to Journey Medical Corporation","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"},{"orgOrder":0,"company":"Maruho","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Maruho Obtained Regulatory Approval for Mitchga, the First Antibody Targeting IL-31 for Itching Associated with Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Large molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"},{"orgOrder":0,"company":"Maruho","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Incyte and Maruho Announce Strategic Alliance Agreement for Ruxolitinib Cream in Japan","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"},{"orgOrder":0,"company":"Maruho","sponsor":"BiomX","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IND Accepted to Conduct Clinical Testing of BX005 for the Treatment of Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"JAPAN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Maruho","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Maruho Launched in Japan the Anti-IL-31 Receptor A Humanized Monoclonal Antibody Mitchga for the Treatment of Itching Associated with Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Large molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"},{"orgOrder":0,"company":"Maruho","sponsor":"Evommune","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Evommune Announces Strategic Collaboration with Maruho to Develop and Commercialize MRGPRX2 Antagonist EVO756 in Japan","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical"},{"orgOrder":0,"company":"Maruho","sponsor":"AOBiome Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AOB Pharma and Maruho Enter into an Exclusive License Agreement for AOB Pharma's Topical Biologic B244 for the Treatment of Inflammatory Indications Including Atopic Dermatitis in Japan","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"JAPAN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II"}]

Find Clinical Drug Pipeline Developments & Deals by Maruho

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            The agreement aims to develop and commercialize AOB's topical biologic B244, currently preparing for global Phase 3 clinical trials, a therapeutic treatment for dermatological indications including Atopic Dermatitis, for both appearance and pruritus (itch).

            Lead Product(s): B244

            Therapeutic Area: Dermatology Product Name: B244

            Highest Development Status: Phase II Product Type: Large molecule

            Recipient: AOBiome Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement January 05, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The collaboration aims to develop and commercialize EVO756 in Japan. Evommune’s MRGPRX2 antagonist, is an investigational therapy with the potential to be a first-in-class oral treatment for a variety of mast cell mediated disease.

            Lead Product(s): EVO756

            Therapeutic Area: Immunology Product Name: EVO756

            Highest Development Status: Preclinical Product Type: Small molecule

            Recipient: Evommune

            Deal Size: $60.0 million Upfront Cash: Undisclosed

            Deal Type: Collaboration September 27, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Mitchga (Nemolizumab) is the first antibody drug targeting IL-31 receptor A, for the treatment of itching associated with atopic dermatitis (only when existing treatment is insufficiently effective).

            Lead Product(s): Nemolizumab

            Therapeutic Area: Dermatology Product Name: Mitchga

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Chugai Pharmaceutical

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 08, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            BX005 is currently in the final stages of GMP production. The Company continues to expect the first data readout from its Phase 1/2 proof-of-concept trial evaluating the safety and efficacy.

            Lead Product(s): BX005

            Therapeutic Area: Dermatology Product Name: BX005

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Recipient: BiomX

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 11, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Maruho will receive the rights to develop, manufacture and exclusively commercialize ruxolitinib cream, and other potential future topical formulations of ruxolitinib, in autoimmune and inflammatory dermatologic diseases, including vitiligo and atopic dermatitis, in Japan.

            Lead Product(s): Ruxolitinib Phosphate

            Therapeutic Area: Dermatology Product Name: Opzelura

            Highest Development Status: Approved Product Type: Small molecule

            Recipient: Incyte Corporation

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement April 28, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The approval of Mitchga, the first antibody-drug targeting interleukin-31, is based on the results from a Japanese phase III clinical study in patients with moderate to severe AD who are older than 13 years old and are tolerant to existing treatments.

            Lead Product(s): Nemolizumab

            Therapeutic Area: Dermatology Product Name: Mitchga

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Chugai Pharmaceutical

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 28, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            QBREXZA (Rapifort® Wipes 2.5%), is a topical product approved by the U.S. Food and Drug Administration for treatment of primary axillary hyperhidrosis in adult and pediatric populations (ages nine-years and older) and is self-administered by patients.

            Lead Product(s): Glycopyrronium Tosylate

            Therapeutic Area: Dermatology Product Name: Rapifort Wipes

            Highest Development Status: Approved Product Type: Small molecule

            Recipient: Journey Medical Corporation

            Deal Size: $10.0 million Upfront Cash: Undisclosed

            Deal Type: Agreement February 11, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Maruho also entered into a binding agreement for an equity investment in BiomX of $3 million at a premium to the market share price, intended primarily to support the Phase 1/2 study of atopic dermatitis product candidate, BX005, in Japan.

            Lead Product(s): BX005

            Therapeutic Area: Dermatology Product Name: BX005

            Highest Development Status: Preclinical Product Type: Large molecule

            Recipient: BiomX

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement October 13, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY